Cargando…
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683707/ https://www.ncbi.nlm.nih.gov/pubmed/26684004 http://dx.doi.org/10.1186/s12985-015-0451-9 |
_version_ | 1782406068231471104 |
---|---|
author | Hu, Zhongjie Liu, Ying Qiu, Lixia Fan, Zuopeng Nie, Wei Liang, Shan Jin, Ronghua |
author_facet | Hu, Zhongjie Liu, Ying Qiu, Lixia Fan, Zuopeng Nie, Wei Liang, Shan Jin, Ronghua |
author_sort | Hu, Zhongjie |
collection | PubMed |
description | BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFNα/RBV treatment. METHODS: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFNα/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. RESULTS: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. CONCLUSIONS: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFNα/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFNα was not observed. |
format | Online Article Text |
id | pubmed-4683707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46837072015-12-19 Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy Hu, Zhongjie Liu, Ying Qiu, Lixia Fan, Zuopeng Nie, Wei Liang, Shan Jin, Ronghua Virol J Research BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFNα/RBV treatment. METHODS: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFNα/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. RESULTS: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. CONCLUSIONS: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFNα/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFNα was not observed. BioMed Central 2015-12-18 /pmc/articles/PMC4683707/ /pubmed/26684004 http://dx.doi.org/10.1186/s12985-015-0451-9 Text en © Hu et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hu, Zhongjie Liu, Ying Qiu, Lixia Fan, Zuopeng Nie, Wei Liang, Shan Jin, Ronghua Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
title | Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
title_full | Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
title_fullStr | Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
title_full_unstemmed | Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
title_short | Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy |
title_sort | kinetic response of wild and mutant core codon 70 strains of hcv genotype 1b to pegylated interferon-α and ribavirin therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683707/ https://www.ncbi.nlm.nih.gov/pubmed/26684004 http://dx.doi.org/10.1186/s12985-015-0451-9 |
work_keys_str_mv | AT huzhongjie kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy AT liuying kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy AT qiulixia kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy AT fanzuopeng kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy AT niewei kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy AT liangshan kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy AT jinronghua kineticresponseofwildandmutantcorecodon70strainsofhcvgenotype1btopegylatedinterferonaandribavirintherapy |